Newsletter Subject

Futures slip in early trading 📉

From

elitetrade.club

Email Address

adam@elitetrade.club

Sent On

Wed, Jun 28, 2023 12:12 PM

Email Preheader Text

This tiny stock could be on course for a major breakout after a recent FDA decision... Good Morning!

This tiny stock could be on course for a major breakout after a recent FDA decision... Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Today is Wednesday, June 28th. I hope you have a great day in the market. Let's get ready to trade! Markets 📈 Stocks rallied back on Tuesday, with the tech-laden Nasdaq leading the push higher. The Dow added 0.6% and the S&P 500 gained 1.1%. The Nasdaq led with a 1.6% gain, and the small-cap Russell 2K rallied 1.4%. Today, futures are down in early morning trading. S&P 500 contracts are currently showing a 0.1% loss. Sponsored [This Up-and-Coming Stock Could Explode 📈]( This early-stage company could be poised to disrupt a $208 billion industry. It has a massive market opportunity, and it could be gearing up for a big expansion push. Best of all, you could get in close to the groundfloor if you act now. [Get the Details & Make Your Move Now.]( Premarket Highlights 🔎 💻 U.S. Weighs New Restrictions on Chip Exports The White House is considering new restrictions on the export of AI-capable chips to China, according to a Wall Street Journal exclusive published this morning. According to the report, the U.S. Commerce Dept. could move to block chip exports from Nvidia, AMD, and other high-tech chip suppliers as soon as next month. What to Watch Today 👀 Chip Stocks Chip stocks are falling in response to the above-mentioned WSJ report, and the news could have a broader impact on the market once the session opens. If these export restrictions come to fruition, it could throw cold water on the red-hot AI chip sector. Major Earnings 💰 General Mills, Inc. [GIS] ... AM Roivant Sciences Ltd. [ROIV] ... AM Unifirst Corporation [UNF] ... AM Signa Sports [SSU] ... AM Micron Technology, Inc. [MU] ... PM Concentrix Corporation [CNXC] ... PM H. B. Fuller Company [FUL] ... PM Worthington Industries, Inc. [WOR] ... PM Franklin Covey Company [FC] ... PM Culp, Inc. [CULP] ... PM Economy 🏗 Advanced retail inventories [May] ... 8:30a Advanced wholesale inventories [May] ... 8:30a Running Hot 🔥 Gainers - Doma Holdings [DOMA] >> +91.0% - iMedia Brands [IMBI] >> +28.8% - Virpax Pharma [VRPX] >> +16.6% - Baosheng Media [BAOS] >> +15.3% Decliners - Ast Spacemobile [ASTS] >> (23.4%) - American Rebel [AREB] >> (25.8%) - Eton Pharma [ETON] >> (18.5%) - Leafly Holdings [LFLY] >> (15.8%) Fiserv [FI] - Last Close: $122.40 Fiserv just announced a promising new partnership. Tata Motors Finance has entered into a partnership with the FinTech firm to "develop and launch new products," according to a Tuesday statement. Tata, and India-based autolender, said the partnership will "streamline the company's digital operations and enhance customer experiences." FI gained 1.8% on Tuesday after the story broke, and it's continuing to gain in this morning's premarket trading session. FI is the top S&P 500 stock in today's premarket with a 2.1% gain. My Take: FI is running hot, and it just broke through a key resistance point. There could be more gains ahead for this under-the-radar performer. Opko Health [OPK] - Last Close: $1.66 A new drug approval is lifting shares of Opko Health. This morning, the company and its partner Pfizer announced the FDA had approved its Ngenla drug compound for pediatric growth hormone deficiency. The once-weekly human growth hormone analog will be available for U.S. prescriptions starting in August, the companies said in their statement. OPK is up 18.6% on news of the drug approval. My Take: OPK has been in a nice positive trend since the start of the month, and it could find new support at $1.90 per share if it can hold onto its gains. Theriva Biologics [TOVX] - Last Close: $0.8276 Theriva Bio is up after clearing a key regulatory milestone. The micro-cap biotech said the FDA granted an Orphan Drug Designation (ODD) for VCN-01 as a treatment for pancreatic cancer. Theriva's VCN-01 is currently undergoing a Phase 2b trial, including 92 adults across 25 sites in Europe and the U.S. Previously, VCN-01 also received an ODD from the FDA as a treatment from retinoblastoma. TOVX is trading actively with a 63.1% gain on the news. My Take: TOVX has been locked in a sideways trading pattern since April, but it's finally beginning to break out. Shares could be on course for more gains in the weeks ahead if they can maintain their momentum. Exponential Fitness [XPOF] - Last Close: $15.72 Exponential Fitness is rebounding from a big sell-off on Tuesday. The gym operator was the subject of a scathing short report from Fuzzy Panda Research that sent shares tumbling to a 37.4% loss yesterday. The report, which called the firm "an abusive franchise that is a house of cards" accused the company and its CEO of wide-ranging dishonestly and fraud. However, Raymond James came out in support of the company, maintaining a strong buy rating and a $40 price target on the stock following the report. Exponential Fitness itself has yet to respond, but shares are already rebounding from Tuesday's selloff. XPOF is up 13.9% in early-morning trading. My Take: I wouldn't touch this one with a ten-foot pole. If you're tempted, I suggest you read [Fuzzy Panda Research's short report]( before you do anything rash. This company could be in trouble. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](

Marketing emails from elitetrade.club

View More
Sent On

31/05/2024

Sent On

31/05/2024

Sent On

30/05/2024

Sent On

30/05/2024

Sent On

30/05/2024

Sent On

29/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.